{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Warren RB"],"funding":["AbbVie"],"pagination":["50-59"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7983954"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["184(1)"],"pubmed_abstract":["<h4>Background</h4>Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.<h4>Objectives</h4>To compare directly the efficacy and safety of risankizumab vs. secukinumab over 52 weeks.<h4>Methods</h4>IMMerge was an international, phase III, multicentre, open-label, efficacy-assessor-blinded, active-comparator study, in which adult patients with chronic, moderate-to-severe plaque psoriasis were randomized in a 1 : 1 ratio to treatment with risankizumab 150 mg or secukinumab 300 mg. Primary efficacy endpoints"],"journal":["The British journal of dermatology"],"pubmed_title":["Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial."],"pmcid":["PMC7983954"],"funding_grant_id":["GPP3"],"pubmed_authors":["Blauvelt A","Warren RB","Paul C","Wu T","Geng Z","Kelly M","Poulin Y","Beeck S"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.","description":"<h4>Background</h4>Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.<h4>Objectives</h4>To compare directly the efficacy and safety of risankizumab vs. secukinumab over 52 weeks.<h4>Methods</h4>IMMerge was an international, phase III, multicentre, open-label, efficacy-assessor-blinded, active-comparator study, in which adult patients with chronic, moderate-to-severe plaque psoriasis were randomized in a 1 : 1 ratio to treatment with risankizumab 150 mg or secukinumab 300 mg. Primary efficacy endpoints","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-04-07T21:23:01.738Z","creation":"2025-04-03T21:33:41.175Z"},"accession":"S-EPMC7983954","cross_references":{"pubmed":["32594522"],"doi":["10.1111/bjd.19341"]}}